NDA 020571 · Pfizer INC
Camptosar
Irinotecan Hydrochloride · Injection
NovelAccelerated approvalPriority reviewLast checked: Nov 19, 2026Latest source record: Apr 4, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1996
Jun 14, 1996
Approved uses
4
Original approval plus efficacy supplements
Registered trials
2,083
325 Phase 3, 315 recruiting
FAERS reports
11,125
10,272 serious, 2,058 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: DIARRHEA and MYELOSUPPRESSION • Early and late forms of diarrhea can occur. Early diarrhea may be accompanied by cholinergic symptoms which may be prevented or ameliorated by atropine. Late diarrhea can be life threatening and should be treated promptly with loperamide. Monitor patients with diarrhea and give fluid and electrolytes as needed. Institute antibiotic therapy if patients develop ileus, fever, or severe neutropenia. Interrupt CAMPTOSAR and reduce subsequent doses if severe diarrhea occurs [see Dosage and Administration (2.2) and Warnings and Precautions (5.1) ] . • Severe myelosuppression may occur [see Warnings and Precautions (5.2) ] . WARNING: DIARRHEA and MYELOSUPPRESSION See full prescribing information for complete boxed warning . • Early and late forms of diarrhea can occur. Early diarrhea may be accompanied by cholinergic symptoms which may be prevented or...
What it is approved for
From the label in effect May 12, 2026.
• CAMPTOSAR is indicated as a component of first-line therapy in combination with 5-fluorouracil (5-FU) and leucovorin (LV) for patients with metastatic carcinoma of the colon or rectum. • CAMPTOSAR is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. CAMPTOSAR is a topoisomerase inhibitor indicated for: • First-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic carcinoma of the colon or rectum. ( 1 ) • Patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. ( 1 )
Mechanism: Irinotecan is a derivative of camptothecin. Camptothecins interact specifically with the enzyme topoisomerase I, which relieves torsional strain in DNA by inducing reversible single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I-DNA complex and prevent religation of these single-strand breaks. Current research suggests that the cytotoxicity of irinotecan is due to double-strand DNA damage produced during DNA synthesis when replication enzymes interact with the ternary complex formed by topoisomerase I, DNA, and either irinotecan or SN-38. Mammalian cells...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 24, 2004 Supplement 21 · Efficacy · priority review Pediatric Written RequestPediatric Medical ReviewPediatric Clinical Pharmacology Review
- Apr 20, 2000 Supplement 9 · Efficacy · priority review ReviewLetterLabel
- Oct 22, 1998 Supplement 8 · Efficacy · priority review ReviewLabelLetter
- Jun 14, 1996 Original approval · Type 1 - New Molecular Entity · priority review Review
3 products under this application
- CAMPTOSAR · IRINOTECAN HYDROCHLORIDE 300MG/15ML (20MG/ML) · INJECTABLE, INJECTION · Prescription · TE AP
- CAMPTOSAR · IRINOTECAN HYDROCHLORIDE 40MG/2ML (20MG/ML) · INJECTABLE, INJECTION · Prescription · TE AP
- CAMPTOSAR · IRINOTECAN HYDROCHLORIDE 100MG/5ML (20MG/ML) · INJECTABLE, INJECTION · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Irinotecan" as an intervention, any sponsor and status, largest first.
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerPivotal-lookingRecruiting
QuantumLeap Healthcare CollaborativeAcademic, hospital or other
NCT01042379 · 5,000 participants (planned) · Start Mar 1, 2010 · Primary completion Dec 2030
Drug: Standard Therapy; AMG 386 with or without Trastuzumab and 44 more · For: Breast Neoplasms; Breast Cancer; Breast Tumors and 8 more
Sites: Birmingham, Alabama; Scottsdale, Arizona; Tucson, Arizona · 42 sites in all
- Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon CancerPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT00079274 · 3,397 participants · Start Feb 2004 · Primary completion Nov 2012
Drug: irinotecan hydrochloride; oxaliplatin and 4 more · For: Adenocarcinoma of the Colon; Stage III Colon Cancer
Sites: Anniston, Alabama; Huntsville, Alabama; Mobile, Alabama · 894 sites in all
- Study of Tumor Tissue Testing in Selecting Treatment for Patients With Metastatic or Locally Advanced Colorectal CancerPivotal-lookingCompleted
Medical Research CouncilGovernment (non-federal)
NCT00975897 · 3,240 participants (planned) · Start Jul 2009 · Primary completion Aug 2010
Drug: bevacizumab; cetuximab and 4 more · For: Colorectal Cancer
Sites: Leeds, United Kingdom; Belfast, United Kingdom; Cardiff, United Kingdom
- Personalizing Chemotherapy Selection After Surgery for Patients With Stage III Colorectal Cancer Using a Blood TestPivotal-lookingActive, not recruiting
UNICANCERAcademic, hospital or other
NCT07340567 · 2,450 participants (planned) · Start Jul 20, 2026 · Primary completion Nov 1, 2032
Drug: Capecitabine; Oxaliplatin and 2 more · For: Colorectal Cancer
Sites: Villejuif, France; Gothenburg, Sweden; Lund, Sweden · 5 sites in all
- Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal CancerPivotal-lookingCompleted
Alliance for Clinical Trials in OncologyAcademic, hospital or other
NCT00265850 · 2,334 participants · Start Nov 2005 · Primary completion Feb 2015
Drug: bevacizumab; cetuximab and 2 more · For: Colorectal Cancer
Sites: Mobile, Alabama; Anchorage, Alaska; Fort Smith, Arkansas · 683 sites in all
- Fluorouracil and Irinotecan With or Without Leucovorin Compared With Observation in Treating Patients Who Have Undergone Surgery for Stage II Colon CancerPivotal-lookingStatus unknown
Federation Francophone de Cancerologie DigestiveAcademic, hospital or other
NCT00091312 · 1,976 participants (planned) · Start Jun 2004
Drug: FOLFIRI regimen; fluorouracil and 2 more · For: Colorectal Cancer
Sites: Cairo, Egypt; Boulogne-Billancourt, France; Dijon, France · 9 sites in all
- Colon Adjuvant Chemotherapy Based on Evaluation of Residual DiseasePivotal-lookingRecruiting
NRG OncologyAcademic, hospital or other
NCT05174169 · 1,912 participants (planned) · Start Jul 8, 2022 · Primary completion Mar 10, 2029
Drug: mFOLFOX6 3-6 month; CAPOX 3 month and 3 more · For: Stage III Colon Cancer
Sites: Birmingham, Alabama; Daphne, Alabama; Fairhope, Alabama · 1,085 sites in all
- Combination Chemotherapy in Treating Patients With Advanced Colorectal CancerPivotal-lookingCompleted
Alliance for Clinical Trials in OncologyAcademic, hospital or other
NCT00003594 · 1,691 participants · Start Oct 1998 · Primary completion Oct 2004
Drug: irinotecan; fluorouracil and 2 more · For: Colorectal Cancer
Sites: Birmingham, Alabama; Mobile, Alabama; Phoenix, Arizona · 466 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea1,417
- off label use884
- nausea810
- vomiting713
- myelosuppression697
- death681
- disease progression575
- febrile neutropenia575
- neutropenia545
- fatigue487
- pyrexia443
- neuropathy peripheral432
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 391 |
| 2005 | 171 |
| 2006 | 151 |
| 2007 | 171 |
| 2008 | 271 |
| 2009 | 309 |
| 2010 | 411 |
| 2011 | 395 |
| 2012 | 576 |
| 2013 | 356 |
| 2014 | 239 |
| 2015 | 444 |
| 2016 | 332 |
| 2017 | 344 |
| 2018 | 425 |
| 2019 | 474 |
| 2020 | 544 |
| 2021 | 544 |
| 2022 | 856 |
| 2023 | 858 |
| 2024 | 1,044 |
| 2025 | 1,106 |
| 2026 | 713 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Camptosar* (Irinotecan HCL*) · HCPCS J9206
2024 spending
$1.6M
Beneficiaries
6,928
46,104 claims
Per beneficiary
$237
2024 ASP limit $2.67 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,970,761 |
| 2021 | $1,725,327 |
| 2022 | $1,632,554 |
| 2023 | $1,542,097 |
| 2024 | $1,645,199 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer.
Kopetz S, Grothey A, Yaeger R, et al. · N Engl J Med 2019 · Clinical Trial, Phase III, Comparative Study
- NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors.
Wang-Gillam A, Hubner RA, Siveke JT, et al. · Eur J Cancer 2019 · Clinical Trial, Phase III, Randomized Controlled Trial
- Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Wang-Gillam A, Li CP, Bodoky G, et al. · Lancet 2016 · Clinical Trial, Phase III, Multicenter Study
- Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic pancreatic cancer: a systematic review and Bayesian network meta-analysis.
Mastrantoni L, Chiaravalli M, Spring A, et al. · Lancet Oncol 2024 · Systematic Review, Comparative Study
- Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurrent Pancreatic Cancer (GENERATE, JCOG1611): A Randomized, Open-Label, Phase II/III Trial.
Ohba A, Ozaka M, Mizusawa J, et al. · J Clin Oncol 2025 · Clinical Trial, Phase II, Randomized Controlled Trial
- Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Loupakis F, Cremolini C, Masi G, et al. · N Engl J Med 2014 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.